Journal article
Prospective ctDNA genotyping for treatment selection in metastatic castration-resistant prostate cancer (mCRPC): The Canadian Cancer Trials Group phase II PC-BETS umbrella study.
Abstract
218
Background: Precision oncology trials in mCRPC rely on genomic profiling of tumor tissue but testing failure rates are 30-40%. Incorporating liquid biopsy screening into trial designs may address limitations of tissue-only genotyping. We report findings from the first 500 plasma samples screened on Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS), a phase II multicenter, eight-arm Canadian umbrella …
Authors
Kwan EM; Rushton MK; Tu W; Hotte SJ; Mukherjee SD; Ong M; Kolinsky MP; Hamilou Z; Winquist E; Ferrario C
Journal
Journal of Clinical Oncology, Vol. 41, No. 6_suppl, pp. 218–218
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 20, 2023
DOI
10.1200/jco.2023.41.6_suppl.218
ISSN
0732-183X